Acer Therapeutics Inc.
222 Third Street
Suite 2240
Cambridge
Massachusetts
02142
United States
Website: http://www.acertx.com/
Email: jdavis@acertx.com
33 articles with Acer Therapeutics Inc.
-
Acer Therapeutics to Virtually Present at Upcoming Investor Conferences
8/25/2020
Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that Acer’s management team will provide a virtual corporate overview at upcoming investor conferences in September,
-
Acer Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
8/13/2020
Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the second quarter ended June 30, 2020,
-
Acer Therapeutics Announces Administration of ACER-001 in a Fasted State Increased Systemic Exposure of Phenylbutyrate in Healthy Volunteer Food Effect Study
7/8/2020
Acer Therapeutics Inc. (Nasdaq: ACER), today announced data from a food effect study in healthy volunteers showing that administration of ACER-001 in a fasted state increased systemic exposure of phenylbutyrate (PBA), phenylacetate (PAA) and phenylacetylglutamine
-
Acer Therapeutics Reports First Quarter 2020 Financial Results and Provides Corporate Update
5/14/2020
Expanded pipeline with addition of emetine for COVID-19; progressed ACER-001, osanetant and EDSIVO™ programs; and entered into stock purchase agreement with Lincoln Park Capital
-
Acer Therapeutics to Develop Emetine as Potential COVID-19 Treatment in Collaboration with National Center for Advancing Translational Sciences, One of the National Institutes of Health
5/11/2020
Targeting Q3 2020 initiation of an adaptive Phase 2/3 trial evaluating emetine in high-risk COVID-19 outpatients, following IND submission and clearance
-
Acer Therapeutics Announces Common Stock Purchase Agreement for up to $15 million with Lincoln Park Capital
4/30/2020
Acer Therapeutics Inc. announced it has entered into a common stock purchase agreement for up to $15 million with Lincoln Park Capital Fund, LLC, a Chicago-based institutional investor.
-
Acer Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
3/18/2020
Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the fourth quarter and full year ended December 31, 2019 and provided an update on the Company’s recent corporate developments.
-
Acer Receives Formal Dispute Resolution Request (FDRR) Response from FDA’s Office of New DrugsOffice of New Drugs denies Acer’s appeal but describes possible paths forward for EDSIVO™
3/18/2020
Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced that the Office of New Drugs (OND) of the U.S. Food and Drug Administration (FDA) has denied Acer’s appeal of the Complete Response Letter (CRL) in relation to the New Drug Application (NDA) for EDSIVO™
-
Clinical Catch-Up: February 24-28
3/2/2020
The month of February ended with a flurry of clinical trial announcements. Here’s a look. -
Acer Therapeutics Announces ACER-001 for Urea Cycle Disorders Trial Shows Bioequivalence to BUPHENYL®
2/24/2020
Anticipate submitting New Drug Application in early 2021 assuming successful completion of additional non clinical work and 12-month long-term stability data
-
Clinical Catch-Up: December 16-20
12/23/2019
Heading into the holidays, there was still plenty of clinical trial news last week. Here’s a look. -
Acer Therapeutics Announces Full Enrollment of Part B in ACER-001 Pivotal Bioavailability and Bioequivalence Trial for Urea Cycle Disorders
12/16/2019
Part A Successfully Completed and Optimal Formulation of ACER-001 Identified Results of Part B Expected in Q1 2020 with a Planned NDA Submission in Q1 2021
-
Acer Therapeutics Reports Third Quarter 2019 Financial Results and Provides Corporate Update
11/13/2019
NEWTON, Mass., Nov. 13, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today reported financial results for the third quarter ended September 30, 2019 and provided an update on the Company’s recent corporate developments. “We have been very active as we continue to progress the development of
-
Clinical Catch-Up: October 28-Nov 1
11/4/2019
Even clinical trial announcements don’t slow down for Halloween. It was a typically busy week. Here’s a look. -
Acer Therapeutics Announces Full Enrollment of Part A in ACER-001 Pivotal Bioavailability and Bioequivalence Trial for Urea Cycle DisordersResults Expected in Q1 2020 with a Planned NDA Submission in Q1 2021
10/28/2019
Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs, today announced full enrollment of Part A in a pivotal trial evaluating bioavailability and bioequivalence of ACER-001 for the treatment of Urea Cycle Disorders (UCDs).
-
FINAL DEADLINE - Acer Therapeutics Inc. (ACER) - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action and Lead Plaintiff Deadline: August 30, 2019
8/27/2019
Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Acer Therapeutics Inc. and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Acer securities purchased between September 25, 2017 and June 24, 2019, inclusive.
-
The Complete Response Letter indicated the company will need to run an “adequate and well-controlled trial to determine whether celiprolol reduces the risk of clinical events in patients with vEDS.”
-
July looks to be a quiet month for the U.S. Food and Drug Administration (FDA), and it sure looks like the agency is trying to get a lot of work done before the July 4 holiday. Here’s a look at the many approvals scheduled for this week.
-
Acer Therapeutics Announces In-license of Osanetant from Sanofi
1/2/2019
Acer acquires worldwide rights to clinical-stage NK3 receptor antagonist
-
Acer Therapeutics, headquartered in Newton, Mass., in-licensed osanetant, a clinical-stage, selective, non-peptide tachykinin NK3 receptor antagonist from Paris-based Sanofi.